Drugs / CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02051257 | Jun 2014 → Mar 2027 expected | diffuse large B-cell lymphoma, mantle cell lymphoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02051257 ↗ |
| Modality | Cell therapy | “Memory enriched T cells will be made from a patient's own T cells that are genetically modified in a laboratory.” NCT02051257 ↗ |
| Route | Intravenous | “Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells intravenously (IV) over 10 minutes on day 2 or 3 following HSCT.” NCT02051257 ↗ |
| Target | CD19 | “CD19-Specific” NCT02051257 ↗ |